Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,220,000 shares, a drop of 10.9% from the September 15th total of 1,370,000 shares. Based on an average trading volume of 274,200 shares, the days-to-cover ratio is presently 4.4 days.

Institutional Trading of Delcath Systems

Several institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the second quarter valued at $370,000. Levin Capital Strategies L.P. lifted its holdings in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock valued at $262,000 after buying an additional 5,969 shares during the period. Renaissance Technologies LLC acquired a new position in Delcath Systems in the second quarter valued at $694,000. Marshall Wace LLP lifted its holdings in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after buying an additional 6,066 shares during the period. Finally, Legato Capital Management LLC acquired a new position in Delcath Systems in the second quarter valued at $966,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Price Performance

Shares of Delcath Systems stock traded up $0.20 during trading on Tuesday, hitting $8.93. The company's stock had a trading volume of 246,782 shares, compared to its average volume of 253,194. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $11.74. The stock has a market cap of $248.13 million, a price-to-earnings ratio of -3.40 and a beta of 0.78. The stock has a 50-day moving average price of $8.95 and a two-hundred day moving average price of $7.60.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $5.00 million. During the same period in the prior year, the firm earned ($0.58) EPS. On average, equities analysts predict that Delcath Systems will post -1.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DCTH has been the topic of a number of research reports. Stephens reaffirmed an "overweight" rating and set a $25.00 target price on shares of Delcath Systems in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Delcath Systems in a research note on Tuesday, August 6th. StockNews.com raised shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, September 27th. Finally, Craig Hallum initiated coverage on shares of Delcath Systems in a research note on Friday, June 28th. They set a "buy" rating and a $18.00 target price on the stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.